Reboxetine Dual-Release Dosage Form for Sustained Plasma Peaks
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Reboxetine, a norepinephrine reuptake inhibitor used as an antidepressant, has rapid absorption and metabolism, leading to a single peak in plasma concentration within 2 hours, which may not provide sustained therapeutic effects throughout the day.
Innovation Solution
Development of dosage forms that administer reboxetine in a manner producing two local maxima in plasma concentration, with the first occurring within 2-6 hours prior to the second, achieved through the use of dual release components or multiple dosage forms administered at specific intervals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If reboxetine is administered as a standard oral dosage form, then rapid absorption is achieved with peak levels within 2 hours, but the duration of action is insufficient to maintain therapeutic concentrations throughout the day
Solution Approach 1:
The patent divides the single dosage form into two distinct components: an immediate-release component that provides rapid absorption and a controlled-release component that sustains drug release. This segmentation allows the formulation to achieve both rapid onset (within 2 hours) and extended duration (multiple peaks over 24 hours) by having each component perform its specialized function
Solution Approach 2:
The patent creates periodic action in drug release by designing the controlled-release component to release reboxetine in a sustained manner over an extended period, producing multiple plasma concentration peaks throughout the day rather than a single peak. This periodic release pattern maintains therapeutic concentrations across different time periods
2Productivity
If a single peak plasma concentration is achieved, then rapid absorption is demonstrated, but sustained therapeutic coverage throughout the day is not provided
Solution Approach 1:
The patent segments the drug delivery system into immediate-release and controlled-release components, where the immediate-release portion ensures rapid absorption efficiency while the controlled-release portion extends the duration of drug presence in the bloodstream through sustained release mechanisms
Solution Approach 2:
The controlled-release component provides continuous drug release over an extended period, ensuring that reboxetine remains present in the bloodstream at therapeutic concentrations throughout the day, thereby maintaining continuous useful action rather than a single transient peak
Data Source
AI summary
Described herein are methods for the administration of reboxetine, or a pharmaceutically acceptable salt thereof, to a human being in need thereof, resulting in a first maximum plasma concentration and a second maximum plasma concentration, wherein the two maxima are separated by a time period of about 2 hours to about 6 hours.